Subscribe

Subscribe

Latest Content

Solar

Storage

Wind

Event Spotlight

BLOGS

DISTRIBUTECH+ RECAP: Energy Storage Utility Case Studies

Webcast

OPINION

RESOURCES

CLARION ENERGY MEDIA

POWER & ENERGY EVENT SERIES

Privacy Policy

Copyright © 2019 - 2021

Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neogenomics Inc (NQ: NEO )

16.26 +0.49 (+3.11%)
Streaming Delayed Price Updated: 3:35 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neogenomics Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022
FT. MYERS, FL / ACCESSWIRE / July 15, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to... 
From NeoGenomics, Inc.
Via AccessWire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Analyst Ratings for NeoGenomics
Analysts have provided the following ratings for NeoGenomics (NASDAQ:NEO) within the last quarter: 
Via Benzinga
NeoGenomics: Q1 Earnings Insights
NeoGenomics (NASDAQ:NEO) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms... 
From NeoGenomics, Inc.
Via AccessWire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
Analyst Ratings for NeoGenomics
Over the past 3 months, 10 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
Via Benzinga
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D 
From NeoGenomics, Inc.
Via AccessWire
NASDAQ:NEO Investor Alert: Investigation over Possible Wrongdoing at NeoGenomics, Inc.
San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Certain directors of NeoGenomics, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NeoGenomics Appoints Lynn Tetrault Interim CEO
FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services,... 
From NeoGenomics, Inc.
Via AccessWire
Earnings Scheduled For May 13, 2022
Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.08 million. 
Via Benzinga
NeoGenomics, Inc. (NASDAQ: NEO) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 05/11/2022 -- NeoGenomics, Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting
FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary
FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From NeoGenomics, Inc.
Via AccessWire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million. 
Via Benzinga
NeoGenomics Reports Revenue of $117 Million in the First Quarter
First-Quarter 2022 Results - Consolidated revenue increased 1% to $117 million; excluding 2021 COVID-19 PCR testing revenue, consolidated revenue increased 3% - Clinical Services revenue increased 2%... 
From NeoGenomics, Inc.
Via AccessWire
Exposures COVID-19
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
FT. MYERS, FL / ACCESSWIRE / April 25, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022
Data demonstrates potential of RaDaR to predict clinical response in stage III urothelial cancer FT. MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of... 
From NeoGenomics, Inc.
Via AccessWire
Earnings Scheduled For April 27, 2022
Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter. 
Via Benzinga
NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D
NeoGenomics continues to add to its state-of-the-art multiomics solutions in world-class biopharma clinical trial and research services for global pharma companies FORT MYERS, FL / ACCESSWIRE / April... 
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022
FT. MYERS, FL / ACCESSWIRE / April 8, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to... 
From NeoGenomics, Inc.
Via AccessWire
38 Stocks Moving In Thursday's Mid-Day Session
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) jumped 57.6% to $1.3515. Ally Bridge Group reported a purchase of 21.176 million shares of MedAvail Holdings for an average price... 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 64.4% to close at $1.41 on Thursday. Ally Bridge Group reported a purchase of 21.176 million shares of MedAvail... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.